Chidamide for relapsed or resistant peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of a peripheral T-cell lymphoma type (not skin-only or leukemia-type).
- You have at least one measurable tumor or lesion on scans at the start of the study.
- Your lymphoma has returned (relapsed) or is resistant after at least one prior whole-body treatment.
- You are between 20 and 75 years old, and you can do most usual activities (ECOG 0–1).
- You can live with the study plan for at least 12 weeks, and you can sign consent forms.
- You have not had certain treatments close to the study start (for example chemotherapy/immunotherapy/target therapy within 4 weeks, and antibody therapy within 12 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination treatment for peripheral T-cell lymphoma, a type of blood cancer. It may help patients who cannot tolerate standard chemotherapy or whose disease has come back.
This study tests a maintenance drug called chidamide, which may help keep your T-cell leukemia or lymphoma from returning after a stem cell transplant. You will take this drug as a pill to see if it extends the time you stay cancer-free.
This trial tests a combination of two drugs, Linperlisib and Chidamide, for people with peripheral T-cell lymphoma that has come back or not improved after at least one previous treatment. The goal is to see if this combination can help control the cancer.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.